SureTrader SureTrader SureTrader
Home > Boards > US OTC > Medical - Healthcare >

Oxis International Inc. (OXIS)

OXIS RSS Feed
Add OXIS Price Alert      Hide Sticky   Hide Intro
Moderator: CashBowski
Search This Board:
Last Post: 1/19/2017 7:44:41 PM - Followers: 132 - Board type: Free - Posts Today: 17


 

Oxis International Inc.

Below shows OXS-1550 WORKING - Soon to enter Phase II with FDA!

Overview

Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.


Management



 

Company Website
http://oxis.com

 


Corporate Overview - Presentation
Fall 2015
Click the link: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10968247


 




 





 

 

OXIS Conference Call  March 31, 2015

CEO Interview with The Wolf of Weedstreet

 

SCIENTIFIC ADVISORY BOARD

XIANG-QUN (SEAN) XIE, M.D., Ph.D., EMBA

Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.

JAMES J. MULE, Ph.D.

Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.

STEPHEN M. CHANG, Ph.D.

Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.

LISA A. HAILE, Ph.D.

Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.

 

Information on Multiple Myeloma & Cannabidiol (CBD)

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells.”

They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”

The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.

 Chart

Stock Information:


 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OXIS
Current Price
Volume:
Bid Ask Day's Range
SureTrader
OXIS News: Current Report Filing (8-k) 01/13/2017 06:01:48 AM
OXIS News: Securities Registration Statement (s-1/a) 12/28/2016 05:22:14 PM
OXIS News: Securities Registration Statement (s-1/a) 11/21/2016 04:21:32 PM
OXIS News: Quarterly Report (10-q) 11/14/2016 05:44:58 PM
OXIS News: Securities Registration Statement (s-1/a) 10/31/2016 09:25:03 AM
PostSubject
#8379   It's informative to look at Cataldo's biography. I simon wagstaff 01/19/17 07:44:41 PM
#8378   Trust isn't built with shareholders when a companies Dip66 01/19/17 06:06:34 PM
#8377   I would say something big has already happened, simon wagstaff 01/19/17 04:23:59 PM
#8376   What ever is happening with OXIS and MCET Dip66 01/19/17 04:16:32 PM
#8375   If trading volume is 5x their cash on Dip66 01/19/17 03:53:45 PM
#8374   Also loading IMLFF, you should take a look.......... mrcraigo 01/19/17 03:17:31 PM
#8373   Why are you asking him? You seem to mrcraigo 01/19/17 03:16:10 PM
#8372   Thanks buddy, glad you got it all figured out.......... mrcraigo 01/19/17 03:14:34 PM
#8371   Simon do you think the CEO of OXIS Dip66 01/19/17 03:11:17 PM
#8370   nonsense.. no one is loading anything.. like Simon Dip66 01/19/17 03:08:49 PM
#8369   Reloading........ in at .10 out and .20........... Ready mrcraigo 01/19/17 03:03:50 PM
#8368   Still loading? Halks1122 01/19/17 02:56:44 PM
#8367   Trading volume is like 5X their cash on hand? simon wagstaff 01/19/17 01:07:19 PM
#8366   CEO of OXIS was the same CEO of Dip66 01/19/17 09:58:00 AM
#8365   after that last pump and dump I am Dip66 01/19/17 09:51:20 AM
#8364   O, and pay themselves, of course! C ya/ll Fibanotch 01/19/17 08:34:56 AM
#8363   this co. is a "share selling machine" that Fibanotch 01/19/17 08:26:31 AM
#8362   did it hit .05 cents yet? Fibanotch 01/18/17 07:03:26 PM
#8361   Hopefully this doesn't end up like MCET at Dip66 01/18/17 03:29:08 PM
#8360   read the report.. you might be right could Dip66 01/18/17 03:26:59 PM
#8359   Should settle in around 6.5 cents. where is simon wagstaff 01/18/17 10:57:54 AM
#8358   Under 10 cents. willlbone 01/18/17 10:09:19 AM
#8357   Just like MCET. Nice long term play, not. simon wagstaff 01/17/17 07:52:58 PM
#8356   Gibba, sorry about your loss. You can always CashBowski 01/17/17 07:07:16 PM
#8355   They took this from .10 to .26 pretty Dip66 01/17/17 07:01:16 PM
#8354   Has become a day play. IMO Gibba 01/17/17 05:19:37 PM
#8353   Wow, that's quite a fade! CashBowski 01/17/17 04:09:37 PM
#8352   Excellent PR. Keep up the good work $OXIS Dip66 01/17/17 02:32:35 PM
#8350   I am sorry, I forgot the part about simon wagstaff 01/17/17 01:39:49 PM
#8348   What specifically did you see in the financials simon wagstaff 01/17/17 12:50:46 PM
#8346   I'm out ..... Gibba 01/17/17 11:16:09 AM
#8345   Inside information? Looks like this is the news simon wagstaff 01/17/17 10:43:42 AM
#8344   news out! Finally! http://www.otcmarkets.com/stock/OXIS/news GreenDoesCure420 01/17/17 09:32:45 AM
#8343   OXIS News! Oxis Biotech Announces Enrollmment of 2 TPX 01/17/17 09:25:53 AM
#8342   Just came out a few days ago. What simon wagstaff 01/13/17 10:03:09 AM
#8341   From reading the financials it seems to me Dip66 01/13/17 12:50:07 AM
#8340   It's a mystery to me also.Fingers crossed it Livelikenotommorow 01/12/17 07:21:46 PM
#8338   Still loading.... and thank you, hope all is mrcraigo 01/12/17 02:07:31 PM
#8337   I'm not seeing any data that supports the Rando3 01/12/17 01:16:48 PM
#8336   Open at .30 tomorrow? Dip66 01/11/17 10:09:05 PM
#8332   Maybe Ill wait till it's back to .10. simon wagstaff 01/11/17 01:08:31 PM
#8331   You're STILL loading? Dude don't you own enough? Halks1122 01/11/17 10:45:27 AM
#8330   Rejected at the 200dma, but still had a CashBowski 01/10/17 07:11:28 PM
#8329   I am, loading since .10........ last raise was mrcraigo 01/10/17 04:06:30 PM
#8328   Crappiest stock alive. brandao 01/10/17 03:56:14 PM
#8327   I'm still here and holding. Starting to point GreenDoesCure420 01/10/17 02:48:09 PM
#8326   Here for $2.00+ not a penny less. Dip66 01/10/17 01:47:26 PM
#8325   OXIS bullish 0.20 stocktrademan 01/10/17 12:29:19 PM
#8324   OXIS. Something coming:) 136 01/10/17 11:34:23 AM
#8323   Just like MCET, throw some shares around, pop simon wagstaff 01/10/17 11:07:27 AM
PostSubject